$JBSS

SANFILIPPO JOHN B & SON INC

No enriched coverage for $JBSS in the last 7 days.

No SEC Form 4 filings for $JBSS in the last 30 days.

Med

SANFILIPPO JOHN B & SON INC (JBSS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

SANFILIPPO JOHN B & SON INC (JBSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0000880117 SANFILIPPO JOHN B & SON INC 0000880117 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earlies

Trail mix and nuts recalled over potential salmonella contamination

John B. Sanfilippo & Son, Inc. has issued a voluntary recall for various trail mix and nut products, including some sold at Target, due to potential Salmonella contamination from a dry milk powder used as seasoning. Although no Salmonella has been detected in the seasoning and no illnesses have been reported, the recall is a precautionary measure. Consumers are advised to dispose of the products or return them for a refund, and aware of Salmonella symptoms, which can be severe for vulnerable populations.

SANFILIPPO JOHN B&SON ($JBSS) Releases Q3 2026 Earnings

SANFILIPPO JOHN B&SON (JBSS) reported strong Q3 2026 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted earnings of $1.43 per share against an estimate of $1.18, and revenue reached $281,780,000, exceeding the $266,041,500 estimate. This news follows a period of mixed institutional investor activity and a recent "Buy" rating from BWS Financial.

JBSS sentiment & insider activity

Recent JBSS coverage spans financial news and corporate actions.

What's driving JBSS

  • Leadership transition is likely to affect near-term governance expectations and investor sentiment, but the filing provides no financial guidance or operational metrics.

    SEC EDGAR 8-K · Jul 16, 2026

  • The recall of trail mix and nuts due to potential Salmonella contamination presents a short-term negative sentiment for John B. Sanfilippo & Son, Inc. (JBSS). The company's stock may experience a bearish movement if investors perceive increased liability or reputational damage.

    WTVR.com · May 8, 2026

  • SANFILIPPO JOHN B&SON (JBSS) reported robust Q3 2026 earnings exceeding expectations, indicating strong operational performance. The stock's bullish sentiment is supported by improved earnings per share and revenue figures.

    Quiver Quantitative · Apr 29, 2026

  • The company reported strong quarterly earnings exceeding estimates and announced a special dividend, indicating financial health and shareholder value enhancement.

    MarketBeat · Apr 29, 2026

  • The reaffirmation of a 'Buy' rating and positive earnings suggest potential upside, but mixed analyst views and current 'Hold' consensus indicate caution.

    MarketBeat · Feb 3, 2026

alphai scores every news story that mentions JBSS with an AI model for sentiment and relevance, and aggregates insider trades from SANFILIPPO JOHN B & SON INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $JBSS

Score
$JBSSMed

SANFILIPPO JOHN B & SON INC (JBSS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

SANFILIPPO JOHN B & SON INC (JBSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0000880117 SANFILIPPO JOHN B & SON INC 0000880117 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earlies

$JBSSMed

Trail mix and nuts recalled over potential salmonella contamination

John B. Sanfilippo & Son, Inc. has issued a voluntary recall for various trail mix and nut products, including some sold at Target, due to potential Salmonella contamination from a dry milk powder used as seasoning. Although no Salmonella has been detected in the seasoning and no illnesses have been reported, the recall is a precautionary measure. Consumers are advised to dispose of the products or return them for a refund, and aware of Salmonella symptoms, which can be severe for vulnerable populations.

SANFILIPPO JOHN B&SON ($JBSS) Releases Q3 2026 Earnings

SANFILIPPO JOHN B&SON (JBSS) reported strong Q3 2026 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted earnings of $1.43 per share against an estimate of $1.18, and revenue reached $281,780,000, exceeding the $266,041,500 estimate. This news follows a period of mixed institutional investor activity and a recent "Buy" rating from BWS Financial.

$JBSSMed

John B. Sanfilippo & Son (NASDAQ:JBSS) Releases Earnings Results, Beats Estimates By $0.27 EPS

John B. Sanfilippo & Son (NASDAQ:JBSS) announced its quarterly earnings, reporting an EPS of $1.43, exceeding analyst estimates of $1.16 by $0.27. The company's revenue reached $281.78 million, surpassing the consensus of $260.83 million. Additionally, John B. Sanfilippo declared a special dividend of $1.50 per share payable on May 21st, with the stock currently holding a "Hold" rating from analysts and an average price target of $109.00.

$JBSSMed

BWS Financial Reiterates Buy Rating for John B. Sanfilippo & Son (NASDAQ:JBSS)

BWS Financial has reaffirmed its "Buy" rating for John B. Sanfilippo & Son (NASDAQ:JBSS), setting a price target of $109, which suggests a potential upside of 36% from its current price. This reiteration comes despite mixed analyst views, with the company currently holding a "Hold" consensus rating according to MarketBeat. John B. Sanfilippo & Son recently surpassed Q4 EPS estimates, reporting $1.53 against an expected $1.36, and institutional investors own a significant portion of its shares.

Related tickers